{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:13:08Z","timestamp":1791180788941,"version":"4.1.0"},"reference-count":38,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.3892\/or.2012.2150","type":"journal-article","created":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T06:47:29Z","timestamp":1353998849000},"page":"646-652","source":"Crossref","is-referenced-by-count":9,"title":["Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737"],"prefix":"10.3892","volume":"29","author":[{"given":"JUSTUS","family":"LIEBER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXANDER","family":"DEWERTH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JULIA","family":"WENZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BETTINA","family":"KIRCHNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CARMEN","family":"EICHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEVEN W.","family":"WARMANN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00d6RG","family":"FUCHS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SORIN","family":"ARMEANU-EBINGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"key20180107214424_b1-or-29-02-0646","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/0003-4819-100-5-704","article-title":"Drugs five years later","volume":"100","author":"Loehrer","year":"1984","journal-title":"Cisplatin Ann Intern Med"},{"key":"key20180107214424_b2-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180107214424_b3-or-29-02-0646","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Pediatric Oncology","volume":"18","author":"Pritchard","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107214424_b4-or-29-02-0646","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1002\/cncr.24668","article-title":"Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears","volume":"115","author":"Sullivan","year":"2009","journal-title":"Cancer"},{"key":"key20180107214424_b5-or-29-02-0646","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children\u2019s Cancer Group and the Pediatric Oncology Group","volume":"18","author":"Ortega","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107214424_b6-or-29-02-0646","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2003.06.003","article-title":"Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2","volume":"40","author":"Perilongo","year":"2004","journal-title":"Eur J Cancer"},{"key":"key20180107214424_b7-or-29-02-0646","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zsiros","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107214424_b8-or-29-02-0646","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(98)90061-5","article-title":"Cumulative toxicities from cisplatin therapy and current cytoprotective measures","volume":"24","author":"Cvitkovic","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"key20180107214424_b9-or-29-02-0646","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"key20180107214424_b10-or-29-02-0646","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/onc.2009.52","article-title":"Mimicking the BH3 domain to kill cancer cells","volume":"27","author":"Chonghaile","year":"2008","journal-title":"Oncogene"},{"key":"key20180107214424_b11-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/pbc.22740","article-title":"Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells","volume":"55","author":"Lieber","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"key20180107214424_b12-or-29-02-0646","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.humpath.2008.10.022","article-title":"Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways","volume":"40","author":"Adesina","year":"2009","journal-title":"Hum Pathol"},{"key":"key20180107214424_b13-or-29-02-0646","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"key20180107214424_b14-or-29-02-0646","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1471-2407-11-362","article-title":"The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma","volume":"11","author":"Lieber","year":"2011","journal-title":"BMC Cancer"},{"key":"key20180107214424_b15-or-29-02-0646","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00383-011-2988-z","article-title":"Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells","volume":"28","author":"Lieber","year":"2012","journal-title":"Pediatr Surg Int"},{"key":"key20180107214424_b16-or-29-02-0646","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"key20180107214424_b17-or-29-02-0646","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/1078-0432.CCR-06-1526","article-title":"The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan","volume":"13","author":"Trudel","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107214424_b18-or-29-02-0646","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"key20180107214424_b19-or-29-02-0646","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","article-title":"The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs","volume":"77","author":"High","year":"2010","journal-title":"Mol Pharmacol"},{"key":"key20180107214424_b20-or-29-02-0646","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/leu.2009.151","article-title":"The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia","volume":"23","author":"Mason","year":"2009","journal-title":"Leukemia"},{"key":"key20180107214424_b21-or-29-02-0646","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"key":"key20180107214424_b22-or-29-02-0646","first-page":"1","article-title":"Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma","volume":"67","author":"Doi","year":"1976","journal-title":"Gann"},{"key":"key20180107214424_b23-or-29-02-0646","first-page":"809","article-title":"Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma","volume":"74","author":"Pietsch","year":"1996","journal-title":"Lab Invest"},{"key":"key20180107214424_b24-or-29-02-0646","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/08880010590964192","article-title":"Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma","volume":"22","author":"Warmann","year":"2005","journal-title":"Pediatr Hematol Oncol"},{"key":"key20180107214424_b25-or-29-02-0646","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/BF00299776","article-title":"Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study","volume":"19","author":"Reynolds","year":"1995","journal-title":"World J Surg"},{"key":"key20180107214424_b26-or-29-02-0646","first-page":"159","article-title":"Differentiated treatment protocols for high- and standard-risk hepatoblastoma - an interim report of the German Liver Tumor Study HB99","volume":"215","author":"Haberle","year":"2003","journal-title":"Klin Padiatr"},{"key":"key20180107214424_b27-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0959-8049(97)00095-6","article-title":"Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology","volume":"33","author":"von Schweinitz","year":"1997","journal-title":"Eur J Cancer"},{"key":"key20180107214424_b28-or-29-02-0646","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol Mol Biol Rev"},{"key":"key20180107214424_b29-or-29-02-0646","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jss.2007.03.054","article-title":"Bcl-2 gene silencing in pediatric epithelial liver tumors","volume":"144","author":"Warmann","year":"2008","journal-title":"J Surg Res"},{"key":"key20180107214424_b30-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0898-6568(99)00071-6","article-title":"The p38 signal transduction pathway: activation and function","volume":"12","author":"Ono","year":"2000","journal-title":"Cell Signal"},{"key":"key20180107214424_b31-or-29-02-0646","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","article-title":"A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma","volume":"26","author":"Chauhan","year":"2007","journal-title":"Oncogene"},{"key":"key20180107214424_b32-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cncr.10858","article-title":"The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model","volume":"95","author":"Warmann","year":"2002","journal-title":"Cancer"},{"key":"key20180107214424_b33-or-29-02-0646","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107214424_b34-or-29-02-0646","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","article-title":"Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma","volume":"16","author":"Hwang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107214424_b35-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-010-1265-5","article-title":"A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies","volume":"66","author":"Paik","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107214424_b36-or-29-02-0646","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107214424_b37-or-29-02-0646","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"key20180107214424_b38-or-29-02-0646","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2012.2150\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:33:03Z","timestamp":1562373183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2012.2150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,27]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,11,27]]},"published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.3892\/or.2012.2150"],"URL":"https:\/\/doi.org\/10.3892\/or.2012.2150","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,27]]}}}